Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pump's daily trading recs, emphasis on short selling -- Ignore unavailable to you. Want to Upgrade?

To: jl46 who wrote (2854)	6/25/2001 3:58:54 PM
From: Michail Shadkin	Read Replies (1) \| Respond to of 6873

JL, I would wait on TARO for a blowoff day, havent seen it yet.

To: jl46 who wrote (2854)	6/25/2001 8:08:11 PM
From: Bocor	Respond to of 6873

Taro got a positive Barron's mention this weekend...probably explains the mini-run today..... Barron's: Congrats on your January picks, Oscar. Taro Pharmaceutical Industries rose 178%, and Pharmaceutical Resources gained 207%. What went right? Schafer: Taro and another company recently obtained approval to manufacture and market the generic version of Lotrisone, a big seller patented by Schering-Plough. The branded product has been in short supply, and Taro and its competitor have been filling the pipeline rapidly. Originally I thought Taro could earn $3-$5 a share sometime in the future, but now the company has a shot at $3 just next year, and could earn more than $5 in the next three to five years. The stock could sell well in excess of $100.